Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00020397
First received: July 11, 2001
Last updated: June 18, 2013
Last verified: January 2005

July 11, 2001
June 18, 2013
November 2000
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00020397 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma
Immunization Of HLA-A*0201 or HLA-DPB1*04 Patients With Metastatic Melanoma Using Epitopes From The ESO-1 Antigen

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.

PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating patients who have refractory metastatic melanoma.

OBJECTIVES:

  • Determine whether an immunologic response can be obtained after administration of ESO-1 peptide vaccine comprising class I , II, or both peptides in HLA-A*201 or HLA-DPB1*04 positive patients with refractory metastatic melanoma expressing ESO-1.
  • Determine the toxicity of this vaccine in these patients.
  • Determine whether prior immunization with this vaccine results in increased clinical responsiveness in patients treated with interleukin-2.

OUTLINE: Patients are assigned to 1 of 3 groups according to HLA type.

  • Group 1 (HLA-A*201 and HLA-DPB1*04 positive): Patients receive ESO-1 peptide vaccine comprising class I (ESO-1:157-165 [165V]) and class II (ESO-1:161-180) peptides subcutaneously once every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
  • Group 2 (HLA-A*201 positive and HLA-DPB1*04 negative):Patients receive ESO-1 peptide vaccine as in group I comprising class I peptide only.
  • Group 3 (HLA-A*201 negative and HLA-DPB1*04 positive):Patients receive ESO-1 peptide vaccine as in group I comprising class II peptide only.

Patients who develop disease progression discontinue vaccinations and receive high-dose interleukin (IL-2) IV over 15 minutes every 8 hours for up to 4 days (maximum of 12 doses). Treatment with IL-2 repeats every 10-14 days for 4 courses in the absence of disease progression (after at least 2 courses) or unacceptable toxicity.

Patients who have stable disease or a mixed or partial response to vaccination or IL-2 therapy may be eligible for additional vaccine therapy. Patients who have a complete response to vaccine therapy are eligible for 1 additional treatment.

Patients are followed at 3 weeks.

PROJECTED ACCRUAL: A total of 45-90 patients (15-30 per treatment group) will be accrued for this study within 1 year.

Interventional
Phase 2
Masking: Open Label
Primary Purpose: Treatment
Melanoma (Skin)
  • Biological: NY-ESO-1 peptide vaccine
  • Biological: aldesleukin
Not Provided
Khong HT, Yang JC, Topalian SL, Sherry RM, Mavroukakis SA, White DE, Rosenberg SA. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother. 2004 Nov-Dec;27(6):472-7.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
July 2005
Not Provided

DISEASE CHARACTERISTICS:

  • Diagnosis of metastatic melanoma that expresses ESO-1 antigen
  • Must have progressed during prior standard treatment
  • Measurable or evaluable disease
  • HLA-A*201 or HLA-DPB1*04 positive

PATIENT CHARACTERISTICS:

Age:

  • 16 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • More than 3 months

Hematopoietic:

  • WBC at least 3,000/mm^3
  • Platelet count at least 90,000/mm^3

Hepatic:

  • SGOT and SGPT less than 3 times normal
  • Bilirubin no greater than 1.6 mg/dL (3.0 mg/dL for patients with Gilbert's syndrome)
  • Hepatitis B surface antigen negative

Renal:

  • Creatinine no greater than 2.0 mg/dL

Cardiovascular:

  • No cardiac ischemia*
  • No myocardial infarction*
  • No cardiac arrhythmias* NOTE: *For interleukin-2 (IL-2) administration

Pulmonary:

  • No obstructive or restrictive pulmonary disease (for IL-2 administration)

Immunologic:

  • No autoimmune disease
  • No active primary or secondary immunodeficiency
  • HIV negative
  • No active systemic infections

Other:

  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No other active major medical illness (for IL-2 administration)

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • No prior ESO-1 immunization

Chemotherapy:

  • Recovered from any prior chemotherapy

Endocrine therapy:

  • No concurrent systemic steroid therapy

Radiotherapy:

  • Recovered from any prior radiotherapy

Surgery:

  • Not specified

Other:

  • At least 3 weeks since any prior systemic therapy for cancer
  • No other concurrent systemic therapy for cancer
Both
16 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00020397
CDR0000068403, NCI-01-C-0032, NCI-2390
Not Provided
Not Provided
National Cancer Institute (NCI)
Not Provided
Study Chair: Steven A. Rosenberg, MD, PhD NCI - Surgery Branch
National Cancer Institute (NCI)
January 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP